Hospital Arnau de Vilanova de Valencia
Hospital Arnau de Vilanova de Valencia
Valencia, Spain7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT05708235 | |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast Cancer | Recruiting | Phase 3 | 2026-08-24 | NCT06382948 | |
| Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype | Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma | Recruiting | Phase 2 | 2026-07-30 | NCT06486883 | |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-29 | NCT06172127 | |
| Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-29 | NCT04733118 | |
| Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-04-22 | NCT06180356 | |
| Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer | Advanced Breast Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2025-12-05 | NCT06612203 |